Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four ...

We recently published a list of Jim Cramer’s Latest Stock Moves: Top 10 Calls. In this article, we are going to take a look ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Johnson & Johnson (JNJ) and ...

Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for ...

We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...

智通财经APP获悉，2025年3月17日，强生 (JNJ.US)在Clinicaltrials.gov网站上注册了IL-23R口服环肽抑制剂JNJ-2113 (Icotrokinra)治疗银屑病关节炎的三期临床试验ICONIC-PsA 1。该三期临床试验计划入组540例银屑病关节炎患者，预计2026年初步完成。

JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 75% based on the firm’s underlying fundamentals and the stock’s ...

We recently compiled a list of the 14 Best Performing Dividend Stocks To Buy Now. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

强生 (JNJ.US)日前宣布，欧洲药品管理局 (EMA)人用药品委员会 (CHMP)已推荐扩展Darzalex (daratumumab)皮下注射 (SC)剂型的适应症，使用皮下注射Darzalex联合硼替佐米、来那度胺和地塞米松 (D-VRd)，一线治疗新确诊的多发性骨髓瘤成年患者。

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...